Type 1 Diabetes Treatment in China: Standard Care & Clinical Trials
China does not currently offer a routine cure for type 1 diabetes. Standard treatment remains insulin-based, increasingly supported by continuous glucose monitoring and automated insulin delivery. What makes China especially interesting to some patients is its active research in islet replacement and stem-cell-derived insulin-producing cells. Type 2 or not sure of your type? Our main guide to diabetes treatment in China covers both.
Short answer: if your type 1 diabetes is well controlled with modern insulin therapy, travelling
to China only for ordinary management may offer little advantage. China becomes more relevant for difficult cases,
severe hypoglycemia, advanced specialist review, complication care, or patients researching a specific islet/cell
trial. A 2024 Chinese first-in-human report achieved sustained insulin independence in one patient, but that is
early research — not a walk-in cure.
✓ No cure guarantee
✓ Standard care separated from research
✓ Trial status checked when relevant
✓ No obligation to book
Type 1 Diabetes Treatment in China: At a Glance
Modern type 1 care centers on insulin, CGM, education and, when appropriate, automated insulin delivery.
ADA 2026 considers CGM standard care for most people with type 1 diabetes and prefers AID for those who can use it safely.
A 2024 Cell report described sustained insulin independence after autologous CiPSC-derived islet transplantation in one patient.
NCT06731218 is a small RGB-5088 islet-cell study at Tianjin First Center Hospital with an estimated enrollment of 10.
Evidence and registry status last checked: September 2026.
What Is the Standard Treatment for Type 1 Diabetes?
Insulin is still the foundation. Modern type 1 diabetes treatment combines insulin replacement
with glucose monitoring, education and technology. The ADA 2026 Standards describe CGM as standard care for most
people with type 1 diabetes and prefer automated insulin delivery systems for people who can use them safely.
| Treatment layer | What it does | Why it matters before considering China |
|---|---|---|
| Basal-bolus insulin | Replaces background and meal-related insulin needs using injections. | A patient should first know whether poor control is caused by regimen, dosing, education or access problems that can be addressed locally. |
| CGM | Provides continuous glucose data, trends, alarms and time-in-range information. | CGM reports give a Chinese specialist or trial team a much clearer picture than HbA1c alone. |
| Automated insulin delivery | Combines CGM, an insulin pump and an algorithm that adjusts insulin delivery. | For many patients, optimizing proven technology is more realistic than pursuing experimental cell therapy. |
| Complication screening | Kidney, eye, cardiovascular, nerve and foot assessment as clinically indicated. | Complications can determine hospital choice, treatment risk and eligibility for experimental studies. |
Can Type 1 Diabetes Be Cured in China?
No routine cure is established. The clinically important China story is not that type 1 diabetes
has been “cured in China,” but that Chinese teams have produced early proof-of-concept results in islet replacement.
Those results still need larger studies, longer follow-up and careful patient selection.
For the evidence behind headlines that China “cured” type 1 diabetes, see the stem-cell study review.
In 2024, researchers reported one-year results from a first-in-human Phase I study (ChiCTR2300072200). A 25-year-old patient received autologous chemically induced pluripotent stem-cell-derived islets beneath the abdominal anterior rectus sheath and achieved sustained insulin independence beginning 75 days after transplantation.
Insulin-producing cells functioned in a human patient
The published case demonstrated engraftment and insulin-independent glycemic control at one-year follow-up. It is a meaningful research milestone.
One patient is not a general cure
The paper was a preliminary one-patient analysis. The patient had a previous liver transplant and was already receiving immunosuppression, which limits how broadly the result can be generalized.
Want the deeper cell-therapy evidence?
Our separate guide compares the published research, current trials and commercial stem-cell offers marketed to diabetes patients.
Prepare a Type 1 case for review
Use this for specialist care, complications, devices, or a specific research question. There is no universal cure claim on this route.
Eligibility and foreign-patient access
There is no universal diabetes-trial or stem-cell eligibility list. Each protocol publishes its own inclusion and exclusion criteria. Recruitment on a registry is not a promise that an international patient can enroll.
| Question | What can be said now | What still needs the site |
|---|---|---|
| Who may be considered | Adults (and, for some pediatric studies only, children) whose diagnosis, C-peptide, hypoglycaemia history and current therapy match a named protocol. Example sourced criteria for RGB-5088 / NCT06731218 include type 1 diabetes, age 18–60, stimulated C-peptide < 0.3 ng/mL, and at least one severe hypoglycaemia in the prior 12 months (public listing; last cross-checked 10 September 2026). | Whether that protocol is still open, whether your labs fit, and whether the site will review overseas files. |
| What may exclude or delay review | Wrong diabetes type for the protocol; untreated proliferative retinopathy; unstable heart or GI disease; active infection or cancer history where the protocol excludes it; inability to attend follow-up. | Site-specific laboratory cut-offs and washout rules. |
| Records usually needed | Diagnosis, year of onset, recent HbA1c, C-peptide and autoantibodies if done, insulin/pump/CGM details, kidney and eye status, medication list, and any prior transplant or immunosuppression. | Certified translations and original imaging if the hospital asks. |
| Can foreigners request prescreening? | Some sites will look at a remote file. That is prescreening, not enrollment. Chinese domestic IND records (for example CTR20244750 for RGB-5088) have also been listed as not yet recruiting even when ClinicalTrials.gov said recruiting — statuses can disagree. | Written confirmation from the study coordinator. |
| Language and remote review | English summaries help. Official screening is usually in Chinese at the hospital. Remote review does not replace on-site consent. | Whether an international-patient office will coordinate. |
| What happens next | File review → site question → hospital reply → only then travel/visa planning. Parkmega does not assign trial slots. | Ethics, insurance, and visit calendar if the site invites you. |
Check whether my case can be reviewed
Sources: ClinicalTrials.gov NCT06731218 public eligibility text; Chinese CTR20244750 status note. Last reviewed 10 September 2026.
A Current Type 1 Diabetes Islet-Cell Trial in China
One of the clearest current examples is NCT06731218, a Phase I RGB-5088 study at Tianjin First Center Hospital. The public ClinicalTrials.gov record lists the study as recruiting, but that does not mean every type 1 patient — or every foreign patient — can enroll.
| Study detail | Public registry information | What it means for a patient |
|---|---|---|
| Registry ID | NCT06731218 | Use the exact ID when contacting the study team; do not rely on a generic “China stem-cell trial” description. |
| Intervention | RGB-5088 islet-cell transplantation under the anterior rectus sheath | This is a defined biological protocol, not a generic IV stem-cell infusion. |
| Phase / enrollment | Phase I · estimated 10 participants | Very early-stage research focused heavily on safety; not a large efficacy trial. |
| Site | Tianjin First Center Hospital | The actual study site matters more than broad lists of “best diabetes hospitals.” |
| Status | Recruiting | Status should still be rechecked immediately before an eligibility inquiry. |
| Selected inclusion signals | Age 18–60; type 1 diabetes; stimulated C-peptide below 0.3 ng/mL; at least one severe hypoglycemia episode within the prior 12 months. | These criteria show why “I have type 1 diabetes” alone is not enough to determine eligibility. |
| Foreign-patient acceptance | Not established by the public registry | The study site must confirm whether an overseas patient can actually be screened and what travel/follow-up is required. |
Trial listing ≠ enrollment. ClinicalTrials.gov tells you that a study exists and provides
eligibility/contact information. The investigator decides whether a patient qualifies. Parkmega can organize
the records and make the inquiry, but cannot promise enrollment.
Do you want us to check this or another China trial?
Send your recent HbA1c, C-peptide, hypoglycemia history, current insulin/device information and the trial ID you are interested in.
Who May Have a Real Reason to Consider China?
A long-haul medical trip should solve a specific problem. For a patient already receiving appropriate modern type 1 diabetes care at home, China is not automatically a better option.
Cases with a defined question
- Repeated severe hypoglycemia despite optimized treatment
- Hypoglycemia unawareness
- Difficult control needing a tertiary specialist review
- Complex kidney, cardiovascular or other complications
- Interest in a specific registered islet/cell study
- A Chinese hospital or trial has already requested your records
Problems that may be better solved locally
- Routine insulin prescription renewal
- Standard carbohydrate-counting education
- Buying ordinary insulin more cheaply
- A generic “stem-cell cure” ad with no named protocol
- A clinic promising insulin independence before reviewing records
- Travelling before the study/hospital confirms eligibility
What Records Matter for Type 1 Diabetes Trial or Hospital Screening?
Core diabetes records
- Age and year of diagnosis
- Latest HbA1c
- Fasting or stimulated C-peptide if available
- Pancreatic autoantibodies if available
- Current total daily insulin dose
- CGM reports / time in range
- Pump or AID system details
Safety and complication records
- Severe hypoglycemia history
- DKA admissions
- Kidney function and urine albumin
- Eye / retinopathy reports
- Cardiovascular history
- Infection / immune history
- Previous organ transplant and immunosuppression if relevant
How Much Does Type 1 Diabetes Treatment in China Cost?
There is no fixed Type 1 package price. The cost depends on whether you need ordinary endocrinology,
CGM/pump evaluation, complication care, hospital admission, transplant-related assessment or experimental-trial screening.
Public Chinese medical prices can be useful benchmarks for individual tests, but an international-patient quote should be based on the named hospital and actual plan. Our separate cost guide includes official examples such as HbA1c and continuous glucose-monitoring charges and explains what travel-related costs can sit outside the hospital bill.
Need a case-specific China estimate?
Send the diagnosis, recent records and what you want assessed. We can request expected costs when a relevant hospital can evaluate the case.
Red Flags in Type 1 Diabetes “Cure” Offers
No named hospital
“Treatment in Beijing” or “a top China clinic” is not enough. Ask for the exact institution and department.
No protocol or trial ID
If a seller invokes “clinical research,” ask for the registry or ethics identifier and compare the exact cell product and route.
Guaranteed insulin independence
A guaranteed outcome offered before record review is inconsistent with the uncertainty and selection criteria of early-stage cell research.
Published paper used as an advertisement
A peer-reviewed Chinese study does not prove that a commercial package uses the same cells, manufacturing, dose or protocol.
Price before eligibility
For a real trial, eligibility is defined by the protocol. A sales quote cannot replace medical screening.
Travel before hospital confirmation
Do not book a treatment trip based only on a facilitator message. The receiving hospital or study team should first confirm the route.
How Parkmega Handles a Type 1 Diabetes Case
Review the records
We identify the diagnosis, current control, complications and whether your request is routine, advanced or research-related.
Choose the pathway
Endocrinology review, complication care, device/technology assessment, or a specific registered trial inquiry.
Contact a named centre
We ask whether the hospital or study team will review an overseas case and what additional information is required.
Plan only after acceptance
Costs, expected stay, invitation/visa and travel planning come after the medical route has been confirmed.
What to Send for a Type 1 Diabetes Case Review
Minimum useful file
- Diagnosis and year diagnosed
- Age
- Latest HbA1c
- Current insulin regimen and total daily dose
- Recent CGM report if available
- C-peptide / antibodies if available
- Major complications
If your interest is experimental treatment
- Severe hypoglycemia history
- DKA history
- Kidney, eye and cardiovascular reports
- Transplant / immunosuppression history
- Trial ID or hospital name if you already found one
- Any commercial stem-cell brochure or quote you received
Have Type 1 Diabetes and Want to Know Whether China Offers a Realistic Option?
Send your recent records and tell us what you are looking for: a specialist second opinion, complication treatment, a specific trial, or verification of a stem-cell offer. We’ll identify the appropriate pathway before you plan travel.
✓ No obligation to book
✓ No cure guarantee
✓ Named-centre review
Related Diabetes Guides
Frequently Asked Questions
Short answers to the questions international Type 1 diabetes patients most often ask about China.
Can Type 1 diabetes be cured in China?
No routine cure is established. China has produced important early islet-replacement research, including a 2024 first-in-human report of sustained insulin independence in one patient, but this is proof of concept rather than a generally available cure.
What is the standard treatment for Type 1 diabetes in China?
Standard care remains insulin-based. Modern management may use multiple daily injections or an insulin pump, continuous glucose monitoring and automated insulin delivery, together with education and screening for complications.
Is there a recruiting Type 1 diabetes stem-cell or islet-cell trial in China?
As checked in September 2026, ClinicalTrials.gov lists NCT06731218 as recruiting at Tianjin First Center Hospital. It is a Phase I study of RGB-5088 islet-cell transplantation with an estimated enrollment of 10 participants. Eligibility is narrow and foreign-patient acceptance must be confirmed with the site.
Who may qualify for the NCT06731218 Type 1 diabetes trial?
The public registry lists key inclusion criteria including age 18–60, Type 1 diabetes, stimulated C-peptide below 0.3 ng/mL and at least one severe hypoglycemia episode within the previous 12 months. The investigator makes the final eligibility decision, and additional exclusion criteria apply.
Can a foreign patient join a Type 1 diabetes trial in China?
Possibly, but a public trial registry usually does not establish practical overseas-patient acceptance. The study site must confirm whether nationality or residency restrictions apply, whether the patient meets medical criteria and whether the required follow-up can be completed.
How much does Type 1 diabetes treatment cost in China?
There is no fixed national Type 1 package price. Cost depends on the hospital, tests, insulin/device evaluation, complications, admission and whether the patient is pursuing standard care or a research pathway. A case-specific hospital estimate is more useful than a generic converted price.
What records should I send for a Type 1 diabetes review in China?
Send your age, year of diagnosis, latest HbA1c, insulin regimen and total daily dose, recent CGM report when available, C-peptide and pancreatic autoantibodies if tested, severe hypoglycemia or DKA history, complication reports and any trial ID or treatment quote you are considering.
Evidence and Primary Sources
- American Diabetes Association — Standards of Care in Diabetes—2026, Section 7: Diabetes Technology. CGM and automated insulin-delivery recommendations; AID is preferred for people with Type 1 diabetes who can safely use it. ADA 2026 — Diabetes Technology.
- American Diabetes Association — Standards of Care in Diabetes—2026, Section 9. Type 1 pharmacologic management and insulin-treatment principles. ADA 2026 — Pharmacologic Approaches.
- Wang S. et al., Cell (2024), PMID 39326417, DOI 10.1016/j.cell.2024.09.004. Preliminary first-in-human Phase I report of autologous chemically induced pluripotent stem-cell-derived islet transplantation in one Type 1 diabetes patient; sustained insulin independence began 75 days after transplantation. PubMed record.
- Peking University School of Life Sciences. University research summary of the 2024 CiPSC-islet publication and its one-year findings. Peking University research summary.
- ClinicalTrials.gov NCT06731218. Phase I RGB-5088 islet-cell transplantation study at Tianjin First Center Hospital; listed as recruiting in the public record checked in September 2026. The registry lists an estimated enrollment of 10 and key inclusion criteria. ClinicalTrials.gov record.
Evidence note: research and trial status can change. A publication proves what happened in the reported study; it does not automatically prove that the same treatment is commercially available or that an overseas patient can enroll.
Medical note: This page is for medical-travel research and hospital matching. It is not medical advice and should not be used to stop insulin or change diabetes treatment without the treating clinical team.
Want Us to Check a China Hospital, Trial or Stem-Cell Offer?
Send your medical records plus any hospital name, trial ID, brochure or quote you already have. We’ll separate standard care from experimental research and identify the next realistic step before you travel.
Standard type 1 care in China is not the same question as a 2026 cure headline. Is there a cure for type 1 diabetes in 2026? is the evidence page. This page stays on care and the China context.